Literature DB >> 28807941

The Rac GTPase in Cancer: From Old Concepts to New Paradigms.

Marcelo G Kazanietz1, Maria J Caloca2.   

Abstract

Rho family GTPases are critical regulators of cellular functions that play important roles in cancer progression. Aberrant activity of Rho small G-proteins, particularly Rac1 and their regulators, is a hallmark of cancer and contributes to the tumorigenic and metastatic phenotypes of cancer cells. This review examines the multiple mechanisms leading to Rac1 hyperactivation, particularly focusing on emerging paradigms that involve gain-of-function mutations in Rac and guanine nucleotide exchange factors, defects in Rac1 degradation, and mislocalization of Rac signaling components. The unexpected pro-oncogenic functions of Rac GTPase-activating proteins also challenged the dogma that these negative Rac regulators solely act as tumor suppressors. The potential contribution of Rac hyperactivation to resistance to anticancer agents, including targeted therapies, as well as to the suppression of antitumor immune response, highlights the critical need to develop therapeutic strategies to target the Rac pathway in a clinical setting. Cancer Res; 77(20); 5445-51. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28807941      PMCID: PMC5645227          DOI: 10.1158/0008-5472.CAN-17-1456

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

Authors:  A J Ridley; A Hall
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion.

Authors:  Inmaculada Navarro-Lérida; Teijo Pellinen; Susana A Sanchez; Marta C Guadamillas; Yinhai Wang; Tuomas Mirtti; Enrique Calvo; Miguel A Del Pozo
Journal:  Dev Cell       Date:  2015-01-29       Impact factor: 12.270

3.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.

Authors:  Benjamin Mizukawa; Junping Wei; Mahesh Shrestha; Mark Wunderlich; Fu-Sheng Chou; Andrea Griesinger; Chad E Harris; Ashish R Kumar; Yi Zheng; David A Williams; James C Mulloy
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

4.  Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer.

Authors:  Maria Soledad Sosa; Cynthia Lopez-Haber; Chengfeng Yang; Hongbin Wang; Mark A Lemmon; John M Busillo; Jiansong Luo; Jeffrey L Benovic; Andres Klein-Szanto; Hiroshi Yagi; J Silvio Gutkind; Ramon E Parsons; Marcelo G Kazanietz
Journal:  Mol Cell       Date:  2010-12-22       Impact factor: 17.970

5.  Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.

Authors:  Verline Justilien; Syed A Ali; Lee Jamieson; Ning Yin; Adrienne D Cox; Channing J Der; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2017-01-19       Impact factor: 31.743

6.  VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients.

Authors:  Ah-Young Kwon; Gwang-Il Kim; Ju-Yeon Jeong; Ji-Ye Song; Kyu-Beom Kwack; Chan Lee; Hae-Youn Kang; Tae-Heon Kim; Jin-Hyung Heo; Hee Jung An
Journal:  Stem Cells Dev       Date:  2015-04-09       Impact factor: 3.272

7.  RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis.

Authors:  Anne Hakem; Otto Sanchez-Sweatman; Annick You-Ten; Gordon Duncan; Andrew Wakeham; Rama Khokha; Tak W Mak
Journal:  Genes Dev       Date:  2005-08-17       Impact factor: 11.361

8.  The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

Authors:  Ian R Watson; Liren Li; Peter K Cabeceiras; Mozhdeh Mahdavi; Tony Gutschner; Giannicola Genovese; Guocan Wang; Zhuangna Fang; James M Tepper; Katherine Stemke-Hale; Kenneth Y Tsai; Michael A Davies; Gordon B Mills; Lynda Chin
Journal:  Cancer Res       Date:  2014-07-23       Impact factor: 12.701

9.  VAV3 mediates resistance to breast cancer endocrine therapy.

Authors:  Helena Aguilar; Ander Urruticoechea; Pasi Halonen; Kazuma Kiyotani; Taisei Mushiroda; Xavier Barril; Jordi Serra-Musach; Abul Islam; Livia Caizzi; Luciano Di Croce; Ekaterina Nevedomskaya; Wilbert Zwart; Josefine Bostner; Elin Karlsson; Gizeh Pérez Tenorio; Tommy Fornander; Dennis C Sgroi; Rafael Garcia-Mata; Maurice P H M Jansen; Nadia García; Núria Bonifaci; Fina Climent; María Teresa Soler; Alejo Rodríguez-Vida; Miguel Gil; Joan Brunet; Griselda Martrat; Laia Gómez-Baldó; Ana I Extremera; Agnes Figueras; Josep Balart; Robert Clarke; Kerry L Burnstein; Kathryn E Carlson; John A Katzenellenbogen; Miguel Vizoso; Manel Esteller; Alberto Villanueva; Ana B Rodríguez-Peña; Xosé R Bustelo; Yusuke Nakamura; Hitoshi Zembutsu; Olle Stål; Roderick L Beijersbergen; Miguel Angel Pujana
Journal:  Breast Cancer Res       Date:  2014-05-28       Impact factor: 6.466

10.  RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.

Authors:  A L Hein; C M Post; Y M Sheinin; I Lakshmanan; A Natarajan; C A Enke; S K Batra; M M Ouellette; Y Yan
Journal:  Oncogene       Date:  2016-05-16       Impact factor: 9.867

View more
  69 in total

Review 1.  CNF1-like deamidase domains: common Lego bricks among cancer-promoting immunomodulatory bacterial virulence factors.

Authors:  Mengfei Ho; Amel Mettouchi; Brenda A Wilson; Emmanuel Lemichez
Journal:  Pathog Dis       Date:  2018-07-01       Impact factor: 3.166

Review 2.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

3.  Identification of a truncated β1-chimaerin variant that inactivates nuclear Rac1.

Authors:  Victoria Casado-Medrano; Laura Barrio-Real; Laura Gutiérrez-Miranda; Rogelio González-Sarmiento; Eladio A Velasco; Marcelo G Kazanietz; María J Caloca
Journal:  J Biol Chem       Date:  2019-12-22       Impact factor: 5.157

4.  Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.

Authors:  Sunetra Das; Rupa Idate; Kathryn E Cronise; Daniel L Gustafson; Dawn L Duval
Journal:  Mol Cancer Ther       Date:  2019-06-07       Impact factor: 6.261

Review 5.  RHO GTPases: from new partners to complex immune syndromes.

Authors:  Rana El Masri; Jérôme Delon
Journal:  Nat Rev Immunol       Date:  2021-02-05       Impact factor: 53.106

Review 6.  The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic.

Authors:  Victoria Casado-Medrano; Martin J Baker; Cynthia Lopez-Haber; Mariana Cooke; Shaofei Wang; Maria J Caloca; Marcelo G Kazanietz
Journal:  Biochem Soc Trans       Date:  2018-07-31       Impact factor: 5.407

7.  Rho GTPases and the emerging role of tunneling nanotubes in physiology and disease.

Authors:  Suli Zhang; Marcelo G Kazanietz; Mariana Cooke
Journal:  Am J Physiol Cell Physiol       Date:  2020-08-26       Impact factor: 4.249

8.  Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification.

Authors:  Lucía Trilla-Fuertes; Ismael Ghanem; Angelo Gámez-Pozo; Joan Maurel; Laura G-Pastrián; Marta Mendiola; Cristina Peña; Rocío López-Vacas; Guillermo Prado-Vázquez; Elena López-Camacho; Andrea Zapater-Moros; Victoria Heredia; Miriam Cuatrecasas; Pilar García-Alfonso; Jaume Capdevila; Carles Conill; Rocío García-Carbonero; Ricardo Ramos-Ruiz; Claudia Fortes; Carlos Llorens; Paolo Nanni; Juan Ángel Fresno Vara; Jaime Feliu
Journal:  Mol Cell Proteomics       Date:  2020-02-27       Impact factor: 5.911

9.  Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice.

Authors:  Javier Reig-López; María Del Mar Maldonado; Matilde Merino-Sanjuan; Ailed M Cruz-Collazo; Jean F Ruiz-Calderón; Victor Mangas-Sanjuán; Suranganie Dharmawardhane; Jorge Duconge
Journal:  Pharmaceutics       Date:  2020-10-15       Impact factor: 6.321

10.  Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.

Authors:  Xuetian Yue; Fangnan Wu; Yanchen Li; Juan Liu; Michael Boateng; Kranthi Mandava; Cen Zhang; Zhaohui Feng; Jimin Gao; Wenwei Hu
Journal:  Cell Cycle       Date:  2020-04-10       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.